Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference
th Annual Global Healthcare Conference.
Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Wednesday, February 24, 2021 at 1:40 p.m. EST / 6:40 p.m. GMT.
A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
An archive of the webcast will be available following the presentation for at least one week on the Investors section of the company s website at www.jazzpharmaceuticals.com.
Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(2)
DUBLIN, Feb. 16, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adult patients with idiopathic hypersomnia. If approved,
Xywav will be the first and only approved treatment in the U.S. for adults with idiopathic hypersomnia.
Xywav received Fast Track designation by the FDA in September 2020 for the treatment of idiopathic hypersomnia. Jazz was granted rolling submission by FDA for this sNDA in December 2020, permitting the submission of portions of the proposed application as they were completed.
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application.
Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021
News provided by
Share this article
Share this article
DUBLIN, Feb. 9, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter 2020 financial results and provide a business and financial update.
Audio webcast/conference call:
International Dial-In Number: +1 503 343 6056
Passcode: 3093553
A replay of the conference call will be available through March 2, 2021, and accessible through one of the following telephone numbers, using the passcode below: